Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MAP kinase-activated protein kinase 5 (MAPKAPK5)
- Target
- MAPKAPK5
- Molecular classification
- Enzyme, Serine/threonine kinase, Kinase, Protein kinase, Signal transduction enzyme
01
Overview
MAP kinase-activated protein kinase 5 is a serine/threonine kinase encoded by the MAPKAPK5 gene in humans. It is activated by phosphorylation through upstream MAP kinases such as ERK and p38, especially in response to cellular stress and proinflammatory cytokines. The enzyme modulates signal transduction pathways by phosphorylating downstream substrates, including HSP27, influencing cellular processes including inflammation, survival, and apoptosis. It has been investigated as a therapeutic target in disorders such as rheumatoid arthritis and may play roles in neurodegenerative and cardiovascular diseases. Reduced levels of MAPKAPK5 have been linked to Alzheimer's disease, though clinical significance is yet to be fully established.
- Other names
- MAPKAP kinase 5MAPKAP-K5MAPKAPK-5MK-5MK5mitogen-activated protein kinase-activated protein kinase 5MAPK-activated protein kinase 5p38-regulated/activated protein kinase (PRAK)NCFD
02
Mechanism of action
Inhibition of MAPKAPK5 kinase activity, leading to modulation of signal transduction pathways involved in inflammation, stress response, and cell proliferation
03
Biological functions
Signal transductionResponse to cellular stressInflammatory responseRegulation of cell proliferationCell survivalApoptosisPhosphorylation of heat shock protein HSP27
04
Disease associations
CancerInflammationNeurodegenerative disease (notably Alzheimer's disease)Rheumatoid arthritisCardiovascular disease
05
Safety considerations
Lack of efficacy observed in rheumatoid arthritis clinical trials (i.e., GLPG-0259), with limited available data on safety profile for other indicationsgeneral kinase inhibition can risk off-target effects
06
Interacting drugs
GLPG-0259 (investigational)
2 more in the full profile.
07
Biomarkers
Reduced MAPKAPK5 levels have been proposed as a biomarker in Alzheimer's diseasepotential use in inflammatory conditions
Beyond the preview
Go deeper on MAP kinase-activated protein kinase 5 (MAPKAPK5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAP kinase-activated protein kinase 5 (MAPKAPK5).